Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for prevalent retinal diseases with major unmet medical needs. Its lead asset, TH103, is an investigational dual-targeting biologic designed for intravitreal delivery to treat exudative and neovascular retinal conditions, including wet age-related macular degeneration, diabetic eye disease, and retinal vein occlusion. TH103 features extended intraocular retention and enhanced VEGF inhibition through optimized binding to VEGF receptor ligands and heparan sulfate proteoglycan anchoring, aiming to reduce the frequency of clinic visits required by existing therapies. The company is advancing TH103 in clinical trials, such as a Phase 1b/2 multi-dose study in neovascular AMD. Kalaris Therapeutics, Inc. addresses significant burdens on patients and caregivers by pursuing treatments that could improve vision preservation with potentially longer-lasting effects. Headquartered in Palo Alto, California, it operates in the ophthalmology sector, targeting transformative solutions for retinal health.